A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2004
11/11/2004	WO2004096182A1 Extended release matrix tablets of carvedilol
11/11/2004	WO2004096152A2 In situ gelling self-reactive materials for embolization
11/11/2004	WO2004096116A2 Diazabicyclononene derivatives
11/11/2004	WO2004080482A3 Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
11/11/2004	WO2004069240A3 Use in therapy of endocannabinoid-like compounds
11/11/2004	WO2004066997A3 Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
11/11/2004	WO2004038407A3 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
11/11/2004	WO2004014849A3 Isosorbide mononitrate compositions and methods of their use
11/11/2004	WO2003059258A3 Compositions and methods for treating heart failure
11/11/2004	WO2003046574A3 Complement c3 precursor biopolymer markers indicative of insulin resistance
11/11/2004	WO2003029220A3 Preparation of an anhydrous quinoline-based cetp inhibitor by crystallization
11/11/2004	WO2000063175A3 Novel process
11/11/2004	US20040225132 Carvedilol
11/11/2004	US20040225130 Imidazolyl derivatives as corticotropin releasing factor inhibitors
11/11/2004	US20040225124 Process for the preparation of 3-spiro'cyclohexam-1,3'-'3h!indolin-2'-one! derivatives
11/11/2004	US20040225123 Substituted phenyl naphthalenes as estrogenic agents
11/11/2004	US20040225118 31 human secreted proteins
11/11/2004	US20040225111 Therapy for osteoporosis
11/11/2004	US20040225018 administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal
11/11/2004	US20040225013 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents
11/11/2004	US20040225006 Useful in treatment and prophylaxis of conditions mediated by s-CD23 or tumor necrosis factor; autoimmune disease, inflammation, allergy
11/11/2004	US20040225001 Imidazolyl derivatives as corticotropin releasing factor inhibitors
11/11/2004	US20040224996 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/11/2004	US20040224985 for controlling weight; pyrrolidine or piperidine compounds
11/11/2004	US20040224980 Compounds used as drugs in solvents as analgesics
11/11/2004	US20040224970 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
11/11/2004	US20040224969 Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds
11/11/2004	US20040224966 Enzyme inhibitors as drugs for cardiovascular disorders, aids, alzheimers disease or urogenital disorders
11/11/2004	US20040224965 Treatment of cardiovascular disorders, thrombosis, surgery and nhe inhibitors
11/11/2004	US20040224961 Novel thiazolo (4,5-D) pyrimidine compounds
11/11/2004	US20040224959 such as N-benzyl-3-[4-(3,3-diphenyl-1-propyl)piperazin-1-yl]-N-methylbenzamide; for inhibition of secretion of apolipoprotein B lipoprotein from the liver; for treatment of hyperlipidemia, pancreatitis
11/11/2004	US20040224956 Crystal of 6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3(2h)-pyridazinone hydrochloride trihydrate
11/11/2004	US20040224954 Substituted 1H-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
11/11/2004	US20040224945 Novel substituted pyrazole derivatives
11/11/2004	US20040224941 Carboxylic acid derivatives and drugs containing the same as the active ingredient
11/11/2004	US20040224929 Novel vitamin D analogs
11/11/2004	US20040224925 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
11/11/2004	US20040224924 Programming a specific course and rate for a parent drug compound's metabolism that leads to an inactive or weakly active and non-toxic metabolite when the parent drug compound is administered, comprising modifying the parent drug compound by forming one or more of a predetermined chemical arrangement
11/11/2004	US20040224914 Administering to an individual suffering from the non-cancerous angiogenesis-related disease an amount of a therapeutic formulation effective to reduce the effective amount of clusterin in the individual
11/11/2004	US20040224911 Transporters and ion channels
11/11/2004	US20040224902 Process for obtaining lignans
11/11/2004	US20040224896 STQ peptides
11/11/2004	US20040224885 Methods of treating hypertension and compositions for use therein
11/11/2004	US20040224877 drug delivery method of deglycosylated Vitamin D binding protein (DBP-maf) for angiogenesis inhibition; anticarcinogenic, antitumor agents
11/11/2004	US20040224424 Nucleotide sequences comprising allelic variant of cytochrome p450 for use in diagnosis and treatment of cell proliferative, nervous system and cardiovascular disorders; pharmacodynamic profiles and drug screening
11/11/2004	US20040224378 Methods for using ADAMTS-12, an integrin and metalloprotease with thrombspondin motifs
11/11/2004	US20040224360 Methods for diagnosing renal disorders
11/11/2004	US20040224356 Novel human enzymes of the metalloprotease family
11/11/2004	US20040224323 PAK5 screening methods
11/11/2004	US20040224314 G-protein coupled receptors
11/11/2004	US20040224023 Compositions and methods for treating or preventing diseases of body passageways
11/11/2004	US20040223975 Methods for treating cardiovascular diseases with botulinum toxin
11/11/2004	US20040223968 inhibiting a condition characterized by monocytic infiltrates such as atherosclerosis by administering an MCP-1 receptor antagonist that binds to an MCP-1 receptor polypeptide, especially a humanized or monoclonal antibody.
11/11/2004	US20040223963 Method for treating ischemic stroke with melatonin
11/11/2004	US20040223960 lipid hydrolyzing protein or polypeptide, particularly the protein lysosomal acid lipase; treating atherosclerosis, Wolman's Disease and Cholesteryl Ester Storage Disease
11/11/2004	US20040223914 comprises void containing vapor of volatile liquid perfluorocarbon, combined with aqueous solution to form contrast agent, for oral/rectal administration or injection; for gastrointestinal imaging/tomography
11/11/2004	CA2524270A1 Method for the production of an n-terminally modified chemotactic factor
11/11/2004	CA2524248A1 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes
11/11/2004	CA2524134A1 Adiponectin production enhancer
11/11/2004	CA2524125A1 Antibiotic tetrahydro-.beta.-carboline derivatives
11/11/2004	CA2523763A1 Fused pyrimidine derivative
11/11/2004	CA2523579A1 Biological pacemaker
11/11/2004	CA2523575A1 Genetic modification of targeted regions of the cardiac conduction system
11/11/2004	CA2521938A1 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors
11/11/2004	CA2521898A1 Diazabicyclononene derivatives
11/11/2004	CA2520839A1 Quinoxalinone-3- one derivatives as orexin receptor antagonists
11/10/2004	EP1475386A2 Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction
11/10/2004	EP1475382A1 Compounds as semaphorin inhibitors
11/10/2004	EP1475376A1 Hair composition containing a pyrimidine-n-oxide derivative and its use to stimulate keratinic fiberes growth and/or preventing their loss
11/10/2004	EP1475102A1 Remedy for hypertension
11/10/2004	EP1475098A1 High-concentration preparation of soluble thrombomodulin
11/10/2004	EP1474445A1 Glycoisoforms of adiponectin and uses thereof
11/10/2004	EP1474442A2 Cytotoxic t-cell epitopes from chlamydia
11/10/2004	EP1474438A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
11/10/2004	EP1474434A2 The eaat2 promoter and uses thereof
11/10/2004	EP1474425A1 Deazapurines and uses thereof
11/10/2004	EP1474420A1 Quinazoline compounds
11/10/2004	EP1474419A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
11/10/2004	EP1474414A1 Dihydro-thia-phenanthrene-carbonyl-guanidines, method for the production thereof, use thereof as a medicament or diagnostic reagent
11/10/2004	EP1474405A2 Process for the preparation of 4-hetero-substituted phenylalanine derivatives
11/10/2004	EP1474402A1 Salts of valsartan
11/10/2004	EP1474398A1 N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use of the same as pharmaceuticals
11/10/2004	EP1474395A1 Nicotinamide derivates useful as p38 inhibitors
11/10/2004	EP1474393A1 Aryl ureas as kinase inhibitors
11/10/2004	EP1474392A1 Polymorphic form xvi of fexofenadine hydrochloride
11/10/2004	EP1474391A1 Water soluble phenylglycine derivatives
11/10/2004	EP1474387A2 Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to ppar alpha activation
11/10/2004	EP1474380A2 4-dedimethylamino tetracycline compounds
11/10/2004	EP1474152A1 Orodispersible pharmaceutical composition comprising ivabradine
11/10/2004	EP1474150A2 Use of 2-alkoxyphenyl-substituted imidazotriazinones
11/10/2004	EP1474147A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
11/10/2004	EP1474145A1 Quinoline derivatives as npy antagonists
11/10/2004	EP1474140A1 2-oxazolamines and their use as 5-ht2b receptor antagonists
11/10/2004	EP1474139A2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/10/2004	EP1474137A1 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
11/10/2004	EP1474134A1 Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ace inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan
11/10/2004	EP1474133A2 Crystalline solids of carvedilol and processes for their preparation
11/10/2004	EP1474125A1 The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure
11/10/2004	EP1474121A2 Small molecule antagonists of bcl2 family proteins
11/10/2004	EP1474119A1 Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta

1 ... 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 ... 1595